Revised SPCs: Ovitrelle (choriogonadotropin alfa) 250 micrograms/0.5 ml prefilled syringe or pen

SPC updated to include rash as a very rare (<1/10,000) immune system disorder related reaction to treatment with choriogonadotropin alfa in the treatment of anovulatory or oligo-ovulatory adult women.

Source:

electronic Medicines compendium